Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

Breast cancer is a heterogeneous disease with distinct molecular subtypes characterized by differential response to targeted and chemotherapeutic agents. Enhanced understanding of the genetic alterations characteristic of different subtypes is needed to pave the way for more personalized administration of therapeutic agents. We have taken a functional genomics approach using a well-characterized panel of breast cancer cell lines to identify putative biomarkers of resistance to antimitotic agents such as paclitaxel and monomethyl-auristatin-E (MMAE). In vitro studies revealed a striking difference in sensitivity to these agents between cell lines from different subtypes, with basal-like cell lines being significantly more sensitive to both agents than luminal or HER2-amplified cell lines. Genome-wide association studies using copy number data from Affymetrix single nucleotide polymorphism arrays identified amplification of the chromosome 17q21 region as being highly associated with resistance to both paclitaxel and MMAE. An unbiased approach consisting of RNA interference and high content analysis was used to show that amplification and concomitant overexpression of the gene encoding the ABCC3 drug transporter is responsible for conferring in vitro resistance to paclitaxel and MMAE. We also show that amplification of ABCC3 is present in primary breast tumors and that it occurs predominantly in HER2-amplified and luminal tumors, and we report on development of a specific fluorescence in situ hybridization assay that may have utility as a predictive biomarker of taxane resistance in breast cancer.

[1]  L. Grove,et al.  Quantitative characterization of mitosis-blocked tetraploid cells using high content analysis. , 2006, Assay and drug development technologies.

[2]  H. Rosing,et al.  Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics , 2006, Clinical Cancer Research.

[3]  Paolo Cappella,et al.  Multiparametric Cell Cycle Analysis by Automated Microscopy , 2006, Journal of biomolecular screening.

[4]  G. Firestone,et al.  Activation and Potentiation of Interferon-γ Signaling by 3,3′-Diindolylmethane in MCF-7 Breast Cancer Cells , 2006, Molecular Pharmacology.

[5]  P. Conte,et al.  The curability of breast cancer and the treatment of advanced disease , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Kylie L. Gorringe,et al.  Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. , 2005, Carcinogenesis.

[7]  John N Weinstein,et al.  Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.

[8]  C. Kieltyka.  November 1 , 1964 .

[9]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[10]  D. Hasenclever,et al.  Role of the progesterone receptor for paclitaxel resistance in primary breast cancer , 2007, British Journal of Cancer.

[11]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[12]  Roman Rouzier,et al.  Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[14]  Lisa A Carey,et al.  Gene-expression analysis and the basal-like breast cancer subtype. , 2007, Future oncology.

[15]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[16]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[17]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[18]  K. Aldape,et al.  Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR , 2004, Genes, chromosomes & cancer.

[19]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[20]  L. O’Driscoll,et al.  Biomarkers and multiple drug resistance in breast cancer. , 2006, Current cancer drug targets.

[21]  D. Foster,et al.  Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. , 2006, Biochemical pharmacology.

[22]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[23]  Larry Norton,et al.  HER2 and response to paclitaxel in node-positive breast cancer. , 2007, The New England journal of medicine.

[24]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[25]  A. Katsnelson.  Cautious welcome for FDA pharmacogenomics guidance , 2005, Nature Biotechnology.

[26]  Luc Girard,et al.  An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. , 2004, Cancer research.

[27]  Hui Peng,et al.  Expression Profiling of ABC Transporters in a Drug-Resistant Breast Cancer Cell Line Using AmpArray , 2005, Molecular Pharmacology.

[28]  Susan J. Ramus,et al.  Common origins of MDA-MB-435 cells from various sources with those shown to have melonoma properties , 2004, Clinical & Experimental Metastasis.

[29]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Wester,et al.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.

[31]  B. Wullich,et al.  Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. , 2005, Clinical chemistry.

[32]  J. Crown,et al.  The taxanes: an update , 2000, The Lancet.

[33]  Z. Hall.  Cancer , 1906, The Hospital.

[34]  Robert Clarke,et al.  Caveolin-1 Tyrosine Phosphorylation Enhances Paclitaxel-mediated Cytotoxicity* , 2007, Journal of Biological Chemistry.

[35]  J. Beijnen,et al.  MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid , 2005, International journal of cancer.

[36]  L. Bain,et al.  Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. , 1999, Cancer research.

[37]  J. Rutka,et al.  Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. , 2000, Journal of neurosurgery.

[38]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Emmanuel Barillot,et al.  Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..

[40]  K. Aldape,et al.  A model of molecular interactions on short oligonucleotide microarrays , 2003, Nature Biotechnology.

[41]  M. Kool,et al.  A family of drug transporters: the multidrug resistance-associated proteins. , 2000, Journal of the National Cancer Institute.

[42]  H. Harputluoglu,et al.  Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer. , 2007, Breast.

[43]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Robert Kincaid,et al.  Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[46]  G. Peters,et al.  Chromosome microdissection identifies genomic amplifications associated with drug resistance in a leukemia cell line: an approach to understanding drug resistance in cancer , 2006, Chromosome Research.

[47]  S. S. Young,et al.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[48]  S. P. Fodor,et al.  Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays , 2004, Nature Methods.

[49]  Rachael Natrajan,et al.  Chromogenic and fluorescent in situ hybridization in breast cancer. , 2007, Human pathology.

[50]  P. Goss,et al.  Breast Cancer Adjuvant Endocrine Therapy , 2007, Cancer journal.

[51]  M F Singer,et al.  LINE-1: a mammalian transposable element. , 1987, Biochimica et biophysica acta.